From Pre-Clinical Studies to Clinical Trials: Generation of Novel Therapies for Pregnancy Complications
Complications of pregnancy represent a significant disease burden, with both immediate and lasting consequences for mother and baby. Two key pregnancy complications, fetal growth restriction (FGR) and preeclampsia (PE), together affect around 10%–15% of all pregnancies worldwide. Despite this high i...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2015-06-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | http://www.mdpi.com/1422-0067/16/6/12907 |
id |
doaj-dbcaf1206445408584e08aee50c09bf9 |
---|---|
record_format |
Article |
spelling |
doaj-dbcaf1206445408584e08aee50c09bf92020-11-25T00:51:37ZengMDPI AGInternational Journal of Molecular Sciences1422-00672015-06-01166129071292410.3390/ijms160612907ijms160612907From Pre-Clinical Studies to Clinical Trials: Generation of Novel Therapies for Pregnancy ComplicationsElizabeth C. Cottrell0Colin P. Sibley1Maternal and Fetal Health Research Centre, Institute of Human Development, University of Manchester, Manchester M13 9WL, UKMaternal and Fetal Health Research Centre, Institute of Human Development, University of Manchester, Manchester M13 9WL, UKComplications of pregnancy represent a significant disease burden, with both immediate and lasting consequences for mother and baby. Two key pregnancy complications, fetal growth restriction (FGR) and preeclampsia (PE), together affect around 10%–15% of all pregnancies worldwide. Despite this high incidence, there are currently no therapies available to treat these pregnancy disorders. Early delivery remains the only intervention to reduce the risk of severe maternal complications and/or stillbirth of the baby; however early delivery itself is associated with increased risk of neonatal mortality and morbidity. As such, there is a pressing need to develop new and effective treatments that can prevent or treat FGR and PE. Animal models have been essential in identifying and screening potential new therapies in this field. In this review, we address recent progress that has been made in developing therapeutic strategies for pregnancy disorders, some of which are now entering clinical trials.http://www.mdpi.com/1422-0067/16/6/12907pregnancyfetal growth restrictionpreeclampsiapreclinical trials in pregnancy |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Elizabeth C. Cottrell Colin P. Sibley |
spellingShingle |
Elizabeth C. Cottrell Colin P. Sibley From Pre-Clinical Studies to Clinical Trials: Generation of Novel Therapies for Pregnancy Complications International Journal of Molecular Sciences pregnancy fetal growth restriction preeclampsia preclinical trials in pregnancy |
author_facet |
Elizabeth C. Cottrell Colin P. Sibley |
author_sort |
Elizabeth C. Cottrell |
title |
From Pre-Clinical Studies to Clinical Trials: Generation of Novel Therapies for Pregnancy Complications |
title_short |
From Pre-Clinical Studies to Clinical Trials: Generation of Novel Therapies for Pregnancy Complications |
title_full |
From Pre-Clinical Studies to Clinical Trials: Generation of Novel Therapies for Pregnancy Complications |
title_fullStr |
From Pre-Clinical Studies to Clinical Trials: Generation of Novel Therapies for Pregnancy Complications |
title_full_unstemmed |
From Pre-Clinical Studies to Clinical Trials: Generation of Novel Therapies for Pregnancy Complications |
title_sort |
from pre-clinical studies to clinical trials: generation of novel therapies for pregnancy complications |
publisher |
MDPI AG |
series |
International Journal of Molecular Sciences |
issn |
1422-0067 |
publishDate |
2015-06-01 |
description |
Complications of pregnancy represent a significant disease burden, with both immediate and lasting consequences for mother and baby. Two key pregnancy complications, fetal growth restriction (FGR) and preeclampsia (PE), together affect around 10%–15% of all pregnancies worldwide. Despite this high incidence, there are currently no therapies available to treat these pregnancy disorders. Early delivery remains the only intervention to reduce the risk of severe maternal complications and/or stillbirth of the baby; however early delivery itself is associated with increased risk of neonatal mortality and morbidity. As such, there is a pressing need to develop new and effective treatments that can prevent or treat FGR and PE. Animal models have been essential in identifying and screening potential new therapies in this field. In this review, we address recent progress that has been made in developing therapeutic strategies for pregnancy disorders, some of which are now entering clinical trials. |
topic |
pregnancy fetal growth restriction preeclampsia preclinical trials in pregnancy |
url |
http://www.mdpi.com/1422-0067/16/6/12907 |
work_keys_str_mv |
AT elizabethccottrell frompreclinicalstudiestoclinicaltrialsgenerationofnoveltherapiesforpregnancycomplications AT colinpsibley frompreclinicalstudiestoclinicaltrialsgenerationofnoveltherapiesforpregnancycomplications |
_version_ |
1725244805049483264 |